000			03001nam a22004575i 4500
001			978-3-0348-0709-8
003			DE-He213
005			20140220082506.0
007			cr nn 008mamaa
008			131114s2014 sz | s |||| 0|eng d
020			_a9783034807098 _9978-3-0348-0709-8
024	7		_a10.1007/978-3-0348-0709-8 _2doi
050		4	_aRM1-950
072		7	_aMMG _2bicssc
072		7	_aMED071000 _2bisacsh
082	0	4	_a615 _223
100	1		_aTrifilieff, Alexandre. _eeditor.
245	1	0	_aIndacaterol _h[electronic resource] : _bThe First Once-daily Long-acting Beta2 Agonist for COPD / _cedited by Alexandre Trifilieff.
264		1	_aBasel : _bSpringer Basel : _bImprint: Springer, _c2014.
300			_aVII, 146 p. 41 illus., 21 illus. in color. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aMilestones in Drug Therapy, _x2296-6056
505	0		_aCurrent Pharmacotherapy for COPD -- The preclinical pharmacology of indacaterol -- The design of the indacaterol molecule -- The early clinical development of Indacaterol -- INHANCE: An adaptive confirmatory study with dose selection at interim -- Phase III clinical efficacy studies – lung function -- Phase III Clinical Efficacy of Indacaterol -- Patient-centered Outcomes -- The history and performance of the Breezhaler device -- What does the future hold for the therapy of COPD?  .
520			_aChronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available. This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.
650		0	_aMedicine.
650		0	_aToxicology.
650		0	_aPneumology.
650	1	4	_aBiomedicine.
650	2	4	_aPharmacology/Toxicology.
650	2	4	_aPneumology/Respiratory System.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783034807081
830		0	_aMilestones in Drug Therapy, _x2296-6056
856	4	0	_uhttp://dx.doi.org/10.1007/978-3-0348-0709-8
912			_aZDB-2-SBL
999			_c92447 _d92447